Vaccine Info

Priorix Vaccine

Authored by
Last reviewed
April 6, 2021

Priorix Description

Priorix is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain), and Wistar RA 27/3 rubella strains of viruses.

Priorix-TETRA combines measles, mumps, rubella, and varicella vaccine, live, attenuated. It includes a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain), Wistar RA 27/3 rubella, and Oka varicella strains of viruses.

Priorix Indication

Priorix is indicated to protect against measles, mumps, and rubella. It works by helping the body to make its own antibodies that protect your child against these diseases. 

Priorix Dosage

Priorix is administered as a subcutaneous or Intramuscular injection in the deltoid region or in the anterolateral area of the thigh. 

A single 0.5 mL dose of the reconstituted vaccine is recommended.

The Canadian Immunization Guide recommends immunization at 12 months of age, or as soon as practicable thereafter.

A second dose of MMR is recommended at least 1 month after the first dose, for the purpose of better measles protection. 

Priorix is currently licensed outside the USA in over 100 countries, and it is recommended for use in individuals aged ≥9 months, according to a 1- or 2-dose schedule depending on the country.

Priorix News

March 24, 2021 - Vaccine manufacturers across the globe have been focusing on partnering with organizations such as WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines. In spite of several governmental initiatives, measles is a leading cause of death among young children. 

January 6, 2021 - ‘Repurposing’ of MMR vaccine floated as COVID-19 preventive

Priorix Clinical Trials

Clinical Trial NCT01702428: Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Clinical Trial NCT02058563: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

Clinical Trial NCT02325310: Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR (BREMEAVAC)

Clinical Trials

No clinical trials found